Arsenic-mediated nephrotoxicity

References

• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28
   PubMed Web of Science ®Google Scholar
• Ferraro PM, Costanzi S, Naticchia A, et al. Low level exposure to cadmium increases the risk of chronic kidney disease: Analysis of the NHANES 1999–2006. BMC Public Health. 2010;10:304
   PubMed Web of Science ®Google Scholar
• Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: A review of the epidemiologic evidence. Kidney Int. 2006;70:2074–2084
   PubMed Web of Science ®Google Scholar
• Hope JH, Hope BE. A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis. J Environ Public Health. 2012;2012:835059
   PubMedGoogle Scholar
• Orth SR, Hallan SI. Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients – Absence of evidence or evidence of absence? Clin J Am Soc Nephrol. 2008;3:226–236
   PubMed Web of Science ®Google Scholar
• Siddarth M, Datta SK, Mustafa M, et al. Increased level of organochlorine pesticides in chronic kidney disease patients of unknown etiology: Role of GSTM1/GSTT1 polymorphism. Chemosphere. 2014;96:174–179
   PubMedGoogle Scholar
• Jelakovic B, Nikolic J, Radovanovic Z, et al. Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant. 2014;29:2020–2027
   PubMed Web of Science ®Google Scholar
• Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: The case for a Mesoamerican nephropathy. Am J Kidney Dis. 2014;63:506–520
   PubMed Web of Science ®Google Scholar
• Weaver VM, Kim NS, Jaar BG, et al. Associations of low-level urine cadmium with kidney function in lead workers. Occup Environ Med. 2011;68:250–256
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hirano S. Metabolism of arsenic and its toxicological relevance. Arch Toxicol. 2013;87:969–979
   PubMed Web of Science ®Google Scholar
• Ferreccio C, Smith AH, Duran V, et al. Case-control study of arsenic in drinking water and kidney cancer in uniquely exposed Northern Chile. Am J Epidemiol. 2013;178:813–818
   PubMed Web of Science ®Google Scholar
• Surdu S, Fitzgerald EF, Bloom MS, et al. Occupational exposure to arsenic and risk of nonmelanoma skin cancer in a multinational European study. Int J Cancer. 2013;133:2182–2191
   PubMedGoogle Scholar
• Chen Y, Graziano JH, Parvez F, et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: Prospective cohort study. BMJ. 2011;342:2431
   PubMed Web of Science ®Google Scholar
• Abhyankar LN, Jones MR, Guallar E, et al. Arsenic exposure and hypertension: A systematic review. Environ Health Perspect. 2012;120:494–500
   PubMed Web of Science ®Google Scholar
• Martin-Pardillos A, Sosa C, Sorribas V. Arsenic increases Pi-mediated vascular calcification and induces premature senescence in vascular smooth muscle cells. Toxicol Sci. 2013;131:641–653
   PubMedGoogle Scholar
• Gribble MO, Howard BV, Umans JG, et al. Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Am J Epidemiol. 2012;176:865–874
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–466
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Day EC. Biomarkers for incident CKD: A new framework for interpreting the literature. Nat Rev Nephrol. 2013;9:478–483
   PubMedGoogle Scholar
• KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–S154
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
   PubMed Web of Science ®Google Scholar
• Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581–590
   PubMed Web of Science ®Google Scholar
• Salmon AH, Ferguson JK, Burford JL, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012;23:1339–1350
   PubMed Web of Science ®Google Scholar
• Zheng LY, Umans JG, Tellez-Plaza M, et al. Urine arsenic and prevalent albuminuria: Evidence from a population-based study. Am J Kidney Dis. 2013;61:385–394
   PubMedGoogle Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010;12:364–368
   PubMed Web of Science ®Google Scholar
• Andersson L, Haraldsson B, Johansson C, et al. Methodological issues on the use of urinary alpha-1-microglobuline in epidemiological studies. Nephrol Dial Transplant. 2008;23:1252–1256
   PubMedGoogle Scholar
• Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010;28:463–469
   PubMed Web of Science ®Google Scholar
• Pallet N, Chauvet S, Chasse JF, et al. Urinary retinol binding protein is a marker of the extent of interstitial kidney fibrosis. PLoS One. 2014;9:e84708
   Google Scholar
• Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011;49:720–728
   PubMed Web of Science ®Google Scholar
• Calatayud M, Barrios JA, Velez D, et al. In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012;25:446–453
   PubMed Web of Science ®Google Scholar
• Argos M, Rathouz PJ, Pierce BL, et al. Dietary B vitamin intakes and urinary total arsenic concentration in the Health Effects of Arsenic Longitudinal Study (HEALS) cohort, Bangladesh. Eur J Nutr. 2010;49:473–481
   PubMed Web of Science ®Google Scholar
• Majumdar S, Maiti A, Karmakar S, et al. Antiapoptotic efficacy of folic acid and vitamin B(1)(2) against arsenic-induced toxicity. Environ Toxicol. 2012;27:351–363
   PubMedGoogle Scholar
• Mitra SR, Mazumder DN, Basu A, et al. Nutritional factors and susceptibility to arsenic-caused skin lesions in West Bengal, India. Environ Health Perspect. 2004;112:1104–1109
   PubMed Web of Science ®Google Scholar
• Liu Z, Boles E, Rosen BP. Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae. J Biol Chem. 2004;279:17312–17318
   PubMed Web of Science ®Google Scholar
• Ravera S, Virkki LV, Murer H, et al. Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements. Am J Physiol Cell Physiol. 2007;293:C606–C620
   PubMed Web of Science ®Google Scholar
• Carbrey JM, Song L, Zhou Y, et al. Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proc Natl Acad Sci USA. 2009;106:15956–15960
   PubMed Web of Science ®Google Scholar
• Thomas DJ. Unraveling arsenic – glutathione connections. Toxicol Sci. 2009;107(2):309–311
   PubMedGoogle Scholar
• He X, Ma Q. Induction of metallothionein I by arsenic via metal-activated transcription factor 1: Critical role of C-terminal cysteine residues in arsenic sensing. J Biol Chem. 2009;284(19):12609–12621
   PubMedGoogle Scholar
• Liu Y, Liu J, Habeebu SM, et al. Metallothionein-I/II null mice are sensitive to chronic oral cadmium-induced nephrotoxicity. Toxicol Sci. 2000;57:167–176
   PubMed Web of Science ®Google Scholar
• Lee TC, Ho IC, Lu WJ, et al. Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem. 2006;281:18401–18407
   PubMedGoogle Scholar
• Jimi S, Uchiyama M, Takaki A, et al. Mechanisms of cell death induced by cadmium and arsenic. Ann NY Acad Sci. 2004;1011:325–331
   PubMedGoogle Scholar
• Tokumoto M, Lee JY, Fujiwara Y, et al. Inorganic arsenic induces apoptosis through downregulation of Ube2d genes and p53 accumulation in rat proximal tubular cells. J Toxicol Sci. 2013;38:815–820
   PubMedGoogle Scholar
• Lu Y, Yuan H, Deng S, et al. Arsanilic acid causes apoptosis and oxidative stress in rat kidney epithelial cells (NRK-52e cells) by the activation of the caspase-9 and -3 signaling pathway. Drug Chem Toxicol. 2014;37:55–62
   PubMed Web of Science ®Google Scholar
• Brazy PC, Balaban RS, Gullans SR, et al. Inhibition of renal metabolism. Relative effects of arsenate on sodium, phosphate, and glucose transport by the rabbit proximal tubule. J Clin Invest. 1980;66:1211–1221
   PubMedGoogle Scholar
• Li Z, Piao F, Liu S, et al. Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice. Exp Toxicol Pathol. 2010;62:543–547
   PubMedGoogle Scholar
• Hossain E, Ota A, Takahashi M, et al. Arsenic upregulates the expression of angiotensin II Type I receptor in mouse aortic endothelial cells. Toxicol Lett. 2013;220:70–75
   PubMedGoogle Scholar
• Tsukamoto H, Parker HR, Gribble DH, et al. Nephrotoxicity of sodium arsenate in dogs. Am J Vet Res. 1983;44:2324–2330
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Habeebu SM, et al. Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. Toxicology. 2000;147:157–166
   PubMed Web of Science ®Google Scholar
• Muehrcke RC, Pirani CL. Arsine-induced anuria. A correlative clinicopathological study with electron microscopic observations. Ann Intern Med. 1968;68:853–866
   PubMed Web of Science ®Google Scholar
• Gerhardt RE, Hudson JB, Rao RN, et al. Chronic renal insufficiency from cortical necrosis induced by arsenic poisoning. Arch Intern Med. 1978;138:1267–1269
   PubMed Web of Science ®Google Scholar
• Lewis DR, Southwick JW, Ouellet-Hellstrom R, et al. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect. 1999;107:359–365
   PubMed Web of Science ®Google Scholar
• Meliker JR, Wahl RL, Cameron LL, et al. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: A standardized mortality ratio analysis. Environ Health. 2007;6:4
   PubMed Web of Science ®Google Scholar
• Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: A case-control study. Am J Kidney Dis. 2009;54:859–870
   PubMed Web of Science ®Google Scholar
• Chen Y, Parvez F, Liu M, et al. Association between arsenic exposure from drinking water and proteinuria: Results from the Health Effects of Arsenic Longitudinal Study. Int J Epidemiol. 2011;40:828–835
   PubMed Web of Science ®Google Scholar
• Robles-Osorio ML, Perez-Maldonado IN, Martin del Campo D, et al. Urinary arsenic levels and risk of renal injury in a cross-sectional study in open population. Rev Invest Clin. 2012;64:609–614
   PubMed Web of Science ®Google Scholar
• de Burbure C, Buchet JP, Leroyer A, et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: Evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect. 2006;114:584–590
   PubMed Web of Science ®Google Scholar
• Buchet JP, Heilier JF, Bernard A, et al. Urinary protein excretion in humans exposed to arsenic and cadmium. Int Arch Occup Environ Health. 2003;76:111–120
   PubMedGoogle Scholar
• Hong F, Jin T, Zhang A. Risk assessment on renal dysfunction caused by co-exposure to arsenic and cadmium using benchmark dose calculation in a Chinese population. Biometals. 2004;17:573–580
   PubMed Web of Science ®Google Scholar
• Nordberg GF, Jin T, Hong F, et al. Biomarkers of cadmium and arsenic interactions. Toxicol Appl Pharmacol. 2005;206:191–197
   PubMed Web of Science ®Google Scholar
• Huang M, Choi SJ, Kim DW, et al. Risk assessment of low-level cadmium and arsenic on the kidney. J Toxicol Environ Health A. 2009;72:1493–1498
   PubMed Web of Science ®Google Scholar
• Prasad GV, Rossi NF. Arsenic intoxication associated with tubulointerstitial nephritis. Am J Kidney Dis. 1995;26:373–376
   PubMed Web of Science ®Google Scholar
• Yu M, Xue J, Li Y, et al. Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol. 2013;87:1025–1035
   Google Scholar
• Mershiba SD, Dassprakash MV, Saraswathy SD. Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats. Mol Biol Rep. 2013;40:3681–3691
   PubMed Web of Science ®Google Scholar
• Prabu SM, Muthumani M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol Biol Rep. 2012;39:11201–11216
   PubMed Web of Science ®Google Scholar
• Bera AK, Rana T, Das S, et al. Mitigation of arsenic-mediated renal oxidative stress in rat by Pleurotus florida lectin. Hum Exp Toxicol. 2011;30:940–951
   PubMedGoogle Scholar
• Messarah M, Saoudi M, Boumendjel A, et al. Green tea extract alleviates arsenic-induced biochemical toxicity and lipid peroxidation in rats. Toxicol Ind Health. 2013;29:349–359
   PubMed Web of Science ®Google Scholar
• Saxena PN, Anand S, Saxena N, et al. Effect of arsenic trioxide on renal functions and its modulation by Curcuma aromatica leaf extract in albino rat. J Environ Biol. 2009;30:527–531
   PubMed Web of Science ®Google Scholar
• Roy A, Manna P, Sil PC. Prophylactic role of taurine on arsenic mediated oxidative renal dysfunction via MAPKs/NF-kappaB and mitochondria dependent pathways. Free Radic Res. 2009;43:995–1007
   PubMed Web of Science ®Google Scholar
• Rizwan S, Naqshbandi A, Farooqui Z, et al. Protective effect of dietary flaxseed oil on arsenic-induced nephrotoxicity and oxidative damage in rat kidney. Food Chem Toxicol. 2014;68C:99–107
   Google Scholar
• Pi J, Yamauchi H, Sun G, et al. Vascular dysfunction in patients with chronic arsenosis can be reversed by reduction of arsenic exposure. Environ Health Perspect. 2005;113:339–341
   PubMedGoogle Scholar